Drugs / EB-DT-NK-UC101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07492628 | Mar 2026 → Jun 2027 expected | renal pelvis/ureter urothelial carcinoma, urinary bladder cancer | Beijing Biotech | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EB-DT-NK-UC101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07492628 ↗ |
| Modality | Cell therapy | “The investigational product in this example is an allogeneic cord-blood-derived CAR-NK cell therapy engineered to co-recognize Nectin-4 and HER2/ERBB2 and to include an...” NCT07492628 ↗ |
| Route | Intravenous | “The product is administered intravenously after lymphodepletion with fludarabine and cyclophosphamide.” NCT07492628 ↗ |
| Target | ERBB2 | “The investigational product in this example is an allogeneic cord-blood-derived CAR-NK cell therapy engineered to co-recognize Nectin-4 and HER2/ERBB2 and to include an...” NCT07492628 ↗ |